However, a multicenter registry and two recent cohort registries have largely reduced this concern, by showing sudden death rates lower than that observed from the disease itself.These concerns about the drug must be viewed from the clinical perspective that disopyramide is generally the last agent that is tried for patients before they are referred for invasive septal reduction with surgical septal myectomy (an open-heart operation) or alcohol septal ablation (a controlled heart attack). Both of these invasive procedures have risk of morbidity and mortality. For selected patients, a trial of oral disopyramide is a reasonable approach before proceeding to invasive septal reduction. Patients who respond to disopyramide are continued on the drug. Those who continue to have disabling symptoms or who experience side effects are promptly referred for septal reduction. Using such a stepped strategy, investigators have reported that survival does not differ from that observed in the age-matched normal United States population. Cardiac adverse effects
Acute heart failure – Disopyramide should not be given to patients with impaired LV systolic function and low ejection fraction. Heart failure is not seen when disopyramide is used in patients with normal or supernormal LV systolic function. Severe hypotension – Disopyramide should not be given to patients with impaired LV systolic function and low ejection fraction. Hypotension is not seen in patients with normal or supernormal LV systolic function. Extracardiac effects
Atropine like effects (anticholinergic)
Dry mouth
Constipation
Urinary retention – Disopyramide should not be given to patients with symptomatic prostatism. Blurred vision
Glaucoma
Rash
AgranulocytosisAdditionally, disopyramide may enhance the hypoglycaemic effect of gliclazide, insulin, and metformin.
See also
Actisomide

References
External links
Disopyramide on RxList